Brief: Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition
08/12/2025 13:07
Dec 8 (Reuters) - Nurix Therapeutics Inc NRIX.O: NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION Source text: ID:nGNX8klpjp Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis